| 1 |
Lund L, Edwards L, Dipchand A, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third adult heart transplantation report-2016; Focus theme: primary diagnostic indications for transplant [J]. Heart Lung Transplant, 2016, 35(10): 1158-1169
|
| 2 |
Lund L, Khush K, Cherikh W, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth adult heart transplantation report-2017; Focus theme: allograft ischemic time [J]. Heart Lung Transplant, 2017, 36(10): 1037-1046.
|
| 3 |
Mehra M, Ventura H, Smart F, et al. New developments in the diagnosis and management of cardiac allograft vasculopathy [J]. Tex Heart Inst J, 1995, 22(2): 138-144.
|
| 4 |
Bruneval P, Angelini A, Miller D, et al. The XIIIth Banff conference on allograft pathology: the Banff 2015 heart meeting report: improving antibody-mediated rejection diagnostics: strengths, unmet needs, and future directions[J]. Am J Transplant, 2017, 17(1): 42-53.
|
| 5 |
王红月，李莉. 移植心脏病理学及其进展[J/CD]. 实用器官移植电子杂志，2017, 5(6): 459-464.
|
| 6 |
李洲斌，臧旺福. 心脏移植物冠状动脉病变的病理及发病机制[J]. 国际心血管病杂志，2010, 37(3): 137-139.
|
| 7 |
Tuuminen R, Dashkevich A, Keränen M, et al. Platelet-derived growth factor-B protects rat cardiac allografts from ischemia-reperfusion injury [J]. Transplantation, 2016, 100(2): 303-313.
|
| 8 |
Orloff S, Hwee Y, Kreklywich C, et al. Cytomegalovirus latency promotes cardiac lymphoid neogenesis and accelerated allograft rejection in CMV naïve recipients [J]. Am J Transplant, 2011, 11(1): 45-55.
|
| 9 |
Schmauss D, Weis M. Cardiac allograft vasculopathy: recent developments [J]. Circulation, 2008, 117(16): 2131-2141.
|
| 10 |
Benck U, Hoeger S, Brinkkoetter PT, et al. Effects of donor pre-treatment with dopamine on survival after heart transplantation: a cohort study of heart transplant recipients nested in a randomized controlled multicenter trial[J]. J Am Coll Cardiol, 2011, 58(17): 1768-1777.
|
| 11 |
Richmond ME, Easterwood R, Singh RK, et al. Low-dose donor dopamine is associated with a decreased risk of right heart failure in pediatric heart transplant recipients[J]. Transplantation, 2016, 100(12): 2729-2734.
|
| 12 |
Li S, Korkmaz-Icöz S, Radovits T, et al. Donor preconditioning after the onset of brain death with dopamine derivate n-octanoyl dopamine improves early posttransplant graft function in the rat [J]. Am J Transplant, 2017, 17(7): 1802-1812.
|
| 13 |
Nikolova A, Kobashigawa J. Cardiac allograft vasculopathy: the enduring enemy of cardiac transplantation [J]. Transplantation, 2019, 103(7): 1338-1348.
|
| 14 |
Zhang T, Azimzadeh A, Sun W, et al. Selective CD28 inhibition modulates alloimmunity and cardiac allograft vasculopathy in anti-CD154-treated monkeys [J]. Transplantation, 2018, 102(3): e90-e100.
|
| 15 |
Zhang A, Wang K, Zhou C, et al. Knockout of microRNA-155 ameliorates the Th1/Th17 immune response and tissue injury in chronic rejection [J]. J Heart Lung Transplant, 2017, 36(2): 175-184.
|
| 16 |
Sullivan JA, Adams AB, Burlingham WJ. The emerging role of TH17 cells in organ transplantation[J]. Transplantation, 2014, 97(5): 483-489.
|
| 17 |
Atalar K, Afzali B, Lord G, et al. Relative roles of Th1 and Th17 effector cells in allograft rejection[J]. Curr Opin Organ Transplant, 2009, 14(1): 23-29.
|
| 18 |
Syrjälä SO, Keränen MA, Tuuminen R, et al. Increased Th17 rather than Th1 alloimmune response is associated with cardiac allograft vasculopathy after hypothermic preservation in the rat[J]. J Heart Lung Transplant, 2010, 29(9): 1047-1057.
|
| 19 |
Wehner J, Morrell CN, Reynolds T, et al. Antibody and complement in transplant vasculopathy[J]. Circ Res, 2007, 100(2): 191-203.
|
| 20 |
Singh N, Van Craeyveld E, Tjwa M, et al. Circulating apoptotic endothelial cells and apoptotic endothelial microparticles independently predict the presence of cardiac allograft vasculopathy [J]. J Am Coll Cardiol, 2012, 60(4): 324-331.
|
| 21 |
Hammond EH, Yowell RL, Nunoda S, et al. Vascular(humoral) rejection in heart transplantation: pathologic observations and clinical implications[J]. J Heart Transplant, 1989, 8(6):430-443.
|
| 22 |
Hammond E, Yowell R, Nunoda S, et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications [J]. J Heart Transplant, 1989, 8(6): 430-443.
|
| 23 |
Mehra MR, Crespo-Leiro MG, Dipchand A, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010[J]. J Heart Lung Transplant, 2010, 29(7): 717-727.
|
| 24 |
Prada-Delgado O, Estévez-Loureiro R, Paniagua-Martín M, et al. Prevalence and prognostic value of cardiac allograft vasculopathy 1 year after heart transplantation according to the ISHLT recommended nomenclature[J]. J Heart Lung Transplant, 2012, 31(3): 332-333.
|
| 25 |
Tona F, Osto E, Famoso G, et al. Coronary microvascular dysfunction correlates with the new onset of cardiac allograft vasculopathy in heart transplant patients with normal coronary angiography [J]. Am J Transplant, 2015, 15(5): 1400-1406.
|
| 26 |
Colvin MM, Cook JL, Chang P, et al. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association[J]. Circulation, 2015, 131(18): 1608-1639.
|
| 27 |
Shah K, Flattery M, Smallfield M, et al. Surveillance endomyocardial biopsy in the modern era produces low diagnostic yield for cardiac allograft rejection [J]. Transplantation, 2015, 99(8): e75-e80.
|
| 28 |
Kobashigawa J, Tobis J, Starling R, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years [J]. J Am Coll Cardiol, 2005, 45(9): 1532-1537.
|
| 29 |
Okada K, Fearon W, Luikart H, et al. Attenuated-signal plaque progression predicts long-term mortality after heart transplantation: IVUS assessment of cardiac allograft vasculopathy [J]. J Am Coll Cardiol, 2016, 68(4): 382-392.
|
| 30 |
Okada K, Kitahara H, Yang H, et al. Paradoxical vessel remodeling of the proximal segment of the left anterior descending artery predicts long-term mortality after heart transplantation [J]. JACC Heart Failure, 2015, 3(12): 942-952.
|
| 31 |
Wever-Pinzon O, Romero J, Kelesidis I, et al. Coronary computed tomography angiography for the detection of cardiac allograft vasculopathy: a meta-analysis of prospective trials [J]. J Am Coll Cardiol, 2014, 63(19): 1992-2004.
|
| 32 |
Lee A, Beaudoin J, Engel L, et al. Assessment of image quality and radiation dose of prospectively ECG-triggered adaptive dual-source coronary computed tomography angiography (cCTA) with arrhythmia rejection algorithm in systole versus diastole: a retrospective cohort study [J]. Int J Cardiovasc Imaging, 2013, 29(6): 1361-1370.
|
| 33 |
Clemmensen T, Holm N, Eiskjær H, et al. Layered fibrotic plaques are the predominant component in cardiac allograft vasculopathy: systematic findings and risk stratification by OCT [J]. JACC Cardiovasc Imaging, 2017, 10(7): 773-784.
|
| 34 |
Chen Z, Pazdernik M, Zhang H, et al. Quantitative 3D analysis of coronary wall morphology in heart transplant patients: OCT-assessed cardiac allograft vasculopathy progression [J]. Med Image Anal, 2018, 50: 95-105.
|
| 35 |
Chih S, Ross H, Alba A, et al. Perfusion cardiac magnetic resonance imaging as a rule-out test for cardiac allograft vasculopathy [J]. Am J Transplant, 2016, 16(10): 3007-3015.
|
| 36 |
Pighi M, Gratta A, Marin F, et al. "Cardiac allograft vasculopathy: pathogenesis, diagnosis and therapy" [J]. Transplant Rev (Orlando), 2020, 34(4): 100569.
|
| 37 |
Lazarus J, Saleh A, Ghannam M, et al. Safety of regadenoson positron emission tomography stress testing in orthotopic heart transplant patients [J]. J Nucl Cardiol, 2020, 27(3): 943-948.
|
| 38 |
Saito A, Novick R, Kiaii B, et al. Early and late outcomes after cardiac retransplantation [J]. Can J Surg, 2013, 56(1): 21-26.
|
| 39 |
Mattei MF, Redonnet M, Gandjbakhch I, et al. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy[J]. J Heart Lung Transplant, 2007, 26(7): 693-699.
|
| 40 |
Delgado D, Miriuka S, Cusimano R, et al. Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction [J]. J Heart Lung Transplant, 2005, 24(2): 166-169.
|
| 41 |
Starling R, Armstrong B, Bridges N, et al. Accelerated allograft vasculopathy with rituximab after cardiac transplantation [J]. J Am Coll Cardiol, 2019, 74(1): 36-51.
|
| 42 |
Grimm M, Rinaldi M, Yonan N, et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients-a large European trial [J]. Am J Transplant, 2006, 6(6): 1387-1397.
|
| 43 |
Eisen H, Kobashigawa J, Starling R, et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial [J]. Am J Transplant, 2013, 13(5): 1203-1216.
|
| 44 |
Stypmann J, Engelen M, Eckernkemper S, et al. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) after heart transplantation: 2 years′ follow-up from the University Hospital Münster [J]. Transplant Proc, 2011, 43(5): 1847-1852.
|
| 45 |
Asleh R, Briasoulis A, Kremers W, et al. Long-term sirolimus for primary immunosuppression in heart transplant recipients [J]. J Am Coll Cardiol, 2018, 71(6): 636-650.
|
| 46 |
Eisen H, Kobashigawa J, Keogh A, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients [J]. J Heart Lung Transplant, 2005, 24(5): 517-525.
|
| 47 |
Felkel T, Smith A, Reichenspurner H, et al. Survival and incidence of acute rejection in heart transplant recipients undergoing successful withdrawal from steroid therapy [J]. J Heart Lung Transplant, 2002, 21(5): 530-539.
|
| 48 |
Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients [J]. J Heart Lung Transplant, 2010, 29(8):914-956.
|
| 49 |
Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation[J]. N Engl J Med, 1995, 333(10):621-627.
|
| 50 |
Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial[J]. Circulation, 1997, 96(5):1398-1402.
|
| 51 |
Luo CM, Chou NK, Chi NH, et al. The effects of statins on cardiac allograft survival[J]. Transplant Proc, 2014, 46(3):920-924.
|
| 52 |
Stojanovic I, Vrtovec B, Radovancevic B, et al. Survival, graft atherosclerosis, and rejection incidence in heart transplant recipients treated with statins: 5-year follow-up [J]. J Heart Lung Transplant, 2005, 24(9): 1235-1238.
|
| 53 |
Vallakati A, Reddy S, Dunlap M, et al. Impact of statin use after heart transplantation: a meta-analysis [J]. Circ Heart Fail, 2016, 9(10):e003265.
|
| 54 |
Hollis I, Reed B, Moranville M. Medication management of cardiac allograft vasculopathy after heart transplantation [J]. Pharmacotherapy, 2015, 35(5): 489-501.
|
| 55 |
Erinc K, Yamani M, Starling R, et al. The effect of combined angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound [J]. J Heart Lung Transplant, 2005, 24(8): 1033-1038.
|
| 56 |
万青，彭易安，刘丹，等. 五甲基槲皮素预处理对大鼠心肌细胞缺氧复氧损伤保护作用的机制研究[J]. 中国临床药理学与治疗学，2013, 18(1): 1-5.
|
| 57 |
梁艳玲，蒋威. 槲皮素的心血管保护作用研究进展[J]. 解剖学研究，2018, 40(5):444-448.
|
| 58 |
吕丽. 基于PI3K/Akt/NF-κb信号通路槲皮素抗动脉粥样硬化作用研究[D]. 长春：吉林大学，2017.
|
| 59 |
李靖，孙楠，孙永慧，等. 锌离子和钙离子对槲皮素与牛血清白蛋白结合作用的影响[J]. 化学工程师，2017, 31(11): 23-25, 19.
|
| 60 |
Tremblay-Gravel M, Racine N, de Denus S, et al. Changes in outcomes of cardiac allograft vasculopathy over 30 years following heart transplantation [J]. JACC Heart failure, 2017, 5(12): 891-901.
|